scholarly journals Scaling for Economists: Lessons from the Non-Adherence Problem in the Medical Literature

2017 ◽  
Vol 31 (4) ◽  
pp. 125-144 ◽  
Author(s):  
Omar Al-Ubaydli ◽  
John A. List ◽  
Danielle LoRe ◽  
Dana Suskind
Keyword(s):  
Production Process ◽  
Energy Saving ◽  
Medical Literature ◽  
Small Scale ◽  
Original Research ◽  
Common Occurrence ◽  
New Production ◽  
General Success ◽  
Research Studies

Economists often conduct experiments that demonstrate the benefits to individuals of modifying their behavior, such as using a new production process at work or investing in energy saving technologies. A common occurrence is for the success of the intervention in these small-scale studies to diminish substantially when applied at a larger scale, severely undermining the optimism advertised in the original research studies. One key contributor to the lack of general success is that the change that has been demonstrated to be beneficial is not adopted to the extent that would be optimal. This problem is isomorphic to the problem of patient non-adherence to medications that are known to be effective. The large medical literature on countermeasures furnishes economists with potential remedies to this manifestation of the scaling problem.

scholarly journals Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand

Vaccines ◽  
2020 ◽  
Vol 9 (1) ◽  
pp. 3
Author(s):  
Zoltán Kis ◽  
Cleo Kontoravdi ◽  
Robin Shattock ◽  
Nilay Shah
Keyword(s):  
Production Process ◽  
Messenger Rna ◽  
Vaccination Campaign ◽  
Vaccine Dose ◽  
Economic Feasibility ◽  
Small Scale ◽  
Production Scale ◽  
Working Volume ◽  
Global Demand ◽  
The Impact

To overcome pandemics, such as COVID-19, vaccines are urgently needed at very high volumes. Here we assess the techno-economic feasibility of producing RNA vaccines for the demand associated with a global vaccination campaign. Production process performance is assessed for three messenger RNA (mRNA) and one self-amplifying RNA (saRNA) vaccines, all currently under clinical development, as well as for a hypothetical next-generation saRNA vaccine. The impact of key process design and operation uncertainties on the performance of the production process was assessed. The RNA vaccine drug substance (DS) production rates, volumes and costs are mostly impacted by the RNA amount per vaccine dose and to a lesser extent by the scale and titre in the production process. The resources, production scale and speed required to meet global demand vary substantially in function of the RNA amount per dose. For lower dose saRNA vaccines, global demand can be met using a production process at a scale of below 10 L bioreactor working volume. Consequently, these small-scale processes require a low amount of resources to set up and operate. RNA DS production can be faster than fill-to-finish into multidose vials; hence the latter may constitute a bottleneck.

Pilot test of environment-friendly catalysts for the DeNOx of low-temperature flue gas from a coal-fired plant

2021 ◽  
Author(s):  
Lin Guo ◽  
Jianjiang Lu ◽  
Yonggang Zhao ◽  
Chengzhi Wang ◽  
Cheng Zhang ◽  
...  
Keyword(s):  
Low Temperature ◽  
Energy Saving ◽  
Flue Gas ◽  
Small Scale ◽  
Pilot Test ◽  
Environment Friendly ◽  
Efficient Environment

Efficient, environment-friendly, and energy-saving low-temperature denitration (DeNOx) catalysts, applicable in practical flue gas, has a widespread market for use in small-scale boilers. A novel Ce-based low-temperature honeycomb catalyst was tested...

Investigation on small-scale low pressure LNG production process

2018 ◽  
Vol 227 ◽  
pp. 672-685 ◽  
Author(s):  
M.A. Ancona ◽  
M. Bianchi ◽  
L. Branchini ◽  
A. De Pascale ◽  
F. Melino ◽  
...  
Keyword(s):  
Production Process ◽  
Low Pressure ◽  
Small Scale

scholarly journals Accelerating manufacturing to start large-scale supply of a new adenovirus-vectored vaccine within 100 days

2021 ◽  
Author(s):  
Carina CD Joe ◽  
Rameswara R Segireddy ◽  
Cathy Oliveira ◽  
Adam Berg ◽  
Yuanyuan Li ◽  
...  
Keyword(s):  
Production Process ◽  
Large Scale ◽  
Scale Up ◽  
Adenovirus Vector ◽  
Drug Substance ◽  
Economic Modelling ◽  
New Production ◽  
Bulk Drug ◽  
Vectored Vaccine ◽  
Manufacturing Network

The Coalition for Epidemic Preparedness Innovations &rsquo &lsquo 100-day moonshot &rsquo aspires to launch a new vaccine within 100 days of pathogen identification. Here, we describe work to optimize adenovirus vector manufacturing for rapid response, by minimizing time to clinical trial and first large-scale supply, and maximizing the output from the available manufacturing footprint. We describe a rapid viral seed expansion workflow that allows vaccine release to clinical trials within 60 days of antigen sequence identification, followed by vaccine release from globally distributed sites within a further 40 days. We also describe a new perfusion-based upstream production process, designed to maximize output while retaining simplicity and suitability for existing manufacturing facilities. This improves upstream volumetric productivity of ChAdOx1 nCoV-19 by around four-fold and remains compatible with the existing downstream process, yielding drug substance sufficient for 10000 doses from each liter of bioreactor capacity. Transition to a new production process across a large manufacturing network is a major task. In the short term, the rapid seed generation workflow could be used with the existing production process. We also use techno-economic modelling to show that, if linear scale-up were achieved, a single cleanroom containing two 2000 L bioreactors running our new perfusion-based process could supply bulk drug substance for around 120 million doses each month, costing <0.20 EUR/dose. We estimate that a manufacturing network with 32000 L of bioreactor capacity could release around 1 billion doses of a new vaccine within 130 days of genomic sequencing of a new pathogen, in a hypothetical surge campaign with suitable prior preparation and resources, including adequate fill-and-finish capacity. This accelerated manufacturing process, along with other advantages such as thermal stability, supports the ongoing value of adenovirus-vectored vaccines as a rapidly adaptable and deployable platform for emergency response.

scholarly journals GENERATING WORKING HYPOTHESES FOR ORIGINAL RESEARCH STUDIES

2020 ◽  
Vol 1 (1) ◽  
pp. 14-19
Author(s):  
Durga Prasanna Misra ◽  
Vikas Agarwal
Keyword(s):  
Sample Size ◽  
Research Study ◽  
Research Proposal ◽  
Original Research ◽  
Proposal A ◽  
Expected Outcome ◽  
Working Hypotheses ◽  
Young Researchers ◽  
Research Studies

A hypothesis is a statement of the expected outcome of a research study, generally based on analysis of prior published knowledge, or with reference to the previous work of the investigators. The hypothesis forms the foundation of a research proposal. A study based, and planned, on a sound hypothesis may have a greater likelihood of meaningfully contributing to science. After the generation of a hypothesis, it is equally important to appropriately design and adequately power a study (by ensuring a sufficient sample size) in order to test the hypothesis. Adhering to principles discussed forthwith shall help young researchers to generate and test their own hypotheses, and these are best learnt with experience.

scholarly journals Production organization capacity of ethnic minorities in northwestern region of Vietnam

2020 ◽  
Vol 210 ◽  
pp. 16004
Author(s):  
Thu Trang Vu ◽  
Dung Vu ◽  
Thi Mai Lan Nguyen
Keyword(s):  
Ethnic Minorities ◽  
Shifting Cultivation ◽  
Production Capacity ◽  
Production Method ◽  
Small Scale ◽  
New Production ◽  
Organization Capacity ◽  
Northwestern Region ◽  
Traditional Production ◽  
Production Organization

Survey results of 1,452 people representing families of 6 ethnic minorities in 11 communes of 7 districts in 7 provinces in the Northwest region shows that the production organization capacity of the ethnic minorities surveyed has changed, but still remains many limitations. The change in production capacity of ethnic minorities is reflected in the fact that the majority of families have produced in a new way (know how to use some machines, use new plant varieties and breeds, apply chemical fertilizers, use pesticides, and some agricultural products produced for sale). The limitations of the production organization capacity of ethnic minority families are shifting cultivation, dibbling, rudimentary production tools, low labor productivity, production by small-scale, autarky, shifting cultivation of wandering hilltribes). If comparing between traditional production method and new production method, the traditional production method is still more prevalent. One of the main causes of this situation is that ethnic minorities live in mountainous areas with difficult transportation, so the main cultivation method is shifting cultivation. The application of machines in production faces many difficulties.

The Research on New and High-Grade Screen-Printing Ceramic Decal Paper under Glaze Color of once Firing

2012 ◽  
Vol 192 ◽  
pp. 275-279
Author(s):  
Bing Feng Yu
Keyword(s):  
Production Process ◽  
Screen Printing ◽  
High Grade ◽  
New Production ◽  
Printing Technology ◽  
Short Line ◽  
Color Problem ◽  
Paper Structure ◽  
Screen Printing Technology

The paper takes self-developed great aqueous inking oil formulated into screen-printing aqueous ceramic ink under glaze color of once firing as the breakthrough point to choose proper decal paper and the best paper structure. It adopts modern screen-printing technology and searches new production process of ceramic decal under glaze color to solve some problems, such as the uselessness of fine lines, the mistakes of the short line, fault ink and color problem during delicate screen-printing and appliqué, and the defects of injury of glaze during appliqué, and to research new and high-grade screen-printing ceramic decal paper under glaze color of once firing.

Sign in / Sign up

Export Citation Format

Share Document